Genfit S.A. | |
Stock Exchange | Other OTC |
EPS |
$1.4 |
Market Cap |
$756.67 M |
Shares Outstanding |
28.05 M |
Public Float |
- |
Genfit S.A. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
28.05 M |
Public Float |
- |
Genfit S.A. | |
Stock Exchange | Euronext Paris |
EPS |
EUR1.25 |
Market Cap |
EUR674.41 M |
Shares Outstanding |
38.83 M |
Public Float |
28.4 M |
Address |
Parc Eurasante Loos Nord-Pas-de-Calais 59120 France |
Employees | - |
Website | http://www.genfit.com |
Updated | 07/08/2019 |
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. Its research and development efforts are focused on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. |